Background To find a better treatment for patent ductus arteriosus (PDA) in premature infants, the present study investigated the synergism of clinical doses of dexamethasone, indomethacin, and rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on the fetal ductus arteriosus (DA) in rats. Methods and Results Dexamethasone (0.3 mg/kg), indomethacin (0.3 mg/kg), and rofecoxib (0.3 mg/kg), alone or in combination, were administered to preterm (d19) and near-term (d21) fetal rats. The ratio of the inner diameter of the DA to that of the main pulmonary artery (PA) (DA/PA) was studied at 2, 4 and 8 h after drug administration, using a rapid whole-body freezing method. In near-term rats, the combined administration of dexamethasone and indomethacin caused severe constriction, with a DA/PA ratio of 0.52±0.08 at 8 h, whereas the DA/PA ratios were 0.83±0.03 and 0.90±0.02 with dexamethasone and indomethacin, respectively. Combined administration of dexamethasone and rofecoxib also caused severe constriction, with a DA/PA ratio of 0.64±0.07 at 8 h, compared with the DA/PA ratio of 0.92±0.03 with rofecoxib alone. Conclusions Combined therapy may be an option in the medical management of PDA in premature infants before considering surgical treatment. (Circ J 2005; 69: 354 -358) 
he ductus arteriosus (DA) is patent in the fetus and closes rapidly after birth, 1 but in the premature infant the DA is less responsive to the vasoconstrictive effect of oxygen and therefore less likely to close spontaneously, especially in infants with respiratory distress syndrome. 2 The classic management of patent ductus arteriosus (PDA) first involves medical and supportive measures; that is, fluid restriction, diuresis, distending airway pressure, and transfusion of packed red blood cells to keep the hematocrit above 0.4. 2 If these measures fail to close the DA, pharmacologic closure is possible with a cyclooxygenase (COX) inhibitor such as indomethacin. Indomethacin, one of the classical non-steroidal anti-inflammatory drugs (NSAIDs), has been widely used to close the PDA in premature infants 3 and infants with other congenital heart defects. 4 However, it has some side-effects such as renal failure, active bleeding and thrombocytopenia, and may fail to close the PDA in some cases. 2 Steroid hormone such as dexamethasone, which has recently been widely used in the perinatal period, reportedly constricted the fetal DA dose-dependently and moderately in preterm and near-term fetal rats. 5 In particular, postnatal dexamethasone therapy reduced the incidence of clinically detectable PDA in preterm infants weighing less than 1,000 g at birth. 6, 7 The recently developed COX-2 inhibitors 8-10 also constricted the DA in fetal lambs 11 and they may have anti-inflammatory properties without the sideeffects. To find a better medical treatment for PDA in premature infants, we studied the synergism of clinical doses of dexamethasone, indomethacin, and rofecoxib, a selective COX-2 inhibitor, on constriction of the fetal DA in rats.
Methods

Animals
Virgin Wistar rats (pregnancy period 21.5 days) were mated overnight from 1,700 to 09.00 h, and the presence of sperm was confirmed in vaginal smears fixed on day 0 (d0) of pregnancy. The rats were fed commercial solid food and water. Treatment of the rats conformed with the guiding principles of the American Physiological Society and the experiment was approved by the Ethical Committee for Animal Experiments at Tokyo Women's Medical University.
Drug Administration
At 09.00 h on d19 or d21 of pregnancy, indomethacin (Sumitomo Chemical Co, Osaka, Japan, 0.3 mg/kg) and rofecoxib (Nippon Merck-Banyu, Tokyo, Japan, 0.3 mg/kg) were administered through an orogastric tube in a suspension of 1 ml water containing 5% gum arabic, and dexamethasone sodium phosphate (Nippon Merck-Banyu, Tokyo, Japan) was injected at a dose of 0.3 mg/kg into the dorsum.
Measurements
To study the in situ morphology of the fetal DA, a rapid whole-body freezing method was used as described previously. 5 Briefly, fetuses were delivered by cesarean section after atlas dislocation of the mother rats, and frozen immediately in acetone cooled to -80°C with dry ice. The body weight of the frozen fetuses was measured. Seven to 8 fetuses were studied per litter. The frozen thorax was cut on a freezing microtome in the frontal plane, and the inner diameters of the ascending aorta, the main pulmonary artery (PA), and the DA were measured with a microscope and a micrometer every 100 m in 10-15 planes. Constriction of the fetal DA was not uniform, but was most severe in the middle or at the aortic end. 5 The narrowest diameter of the DA was used to obtain the ratio of the inner diameter of the DA to that of the PA.
Protocol
In total, 10 studies were performed ( Table 1) . The DA/PA ratio, which was 1.0 in controls at each set interval, was studied at 2, 4 and 8 h after the separate or simultaneous administration of dexamethasone and indomethacin or rofecoxib. Fetuses of 2 litters were studied at each time point. Fetuses of 3-4 litters were studied at 2 h and 8 h when dexamethasone was administered preterm because of the relatively large standard deviation. Administration of dexamethasone and indomethacin in preterm (d19) rats. Dexamethasone caused ductal constriction similar to indomethacin at each interval after administration. There was no significant difference in the constriction between the combined administration of dexamethasone and indomethacin and dexamethasone or indomethacin alone at each interval after administration. Each point: mean ± SEM. Number of fetuses is shown in parentheses.
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Statistics Calculations were performed using the statistical software package Statview v.5.0 (Institute Inc, Cary, NC, USA) and the results are expressed as the mean ± SEM. The significance of differences between groups was determined separately using the Dunnett method. The acceptable level of significance was 5%.
Results
The results of studies 1-5 (preterm rats) are shown in Figs 1 and 2 . In the preterm (d19) rats, dexamethasone and Administration of dexamethasone and rofecoxib in preterm (d19) rats. Rofecoxib caused ductal constriction similar to indomethacin at each interval after administration. The fetal ductus was significantly more constricted with combined administration of dexamethasone and rofecoxib than with dexamethasone or rofecoxib alone at 2 h after administration. Each point: mean ± SEM. Number of fetuses is shown in parentheses. *p<0.05 vs dexamethasone or rofecoxib alone. rofecoxib alone caused ductal constriction similar to indomethacin at each interval. However, there was no significant difference in the constriction of the fetal DA between the combined administration of dexamethasone and indomethacin, and dexamethasone or indomethacin alone at each interval after administration (Fig 1) . The difference was significant at 2 h after the combined administration of dexamethasone and rofecoxib (Fig 2) . The results of studies 6-10 (near-term rats) are shown in Figs 3-5. In the near-term (d21) rats, dexamethasone alone caused ductal constriction similar to indomethacin at each interval. Combined administration of dexamethasone and indomethacin caused a significantly greater ductal constriction, with a DA/PA ratio of 0.56±0.05 (n=16) at 4 h and 0.52± 0.08 (n=16) at 8 h, whereas the DA/PA ratio decreased only to 0.76±0.03 (n=16) and 0.84±0.03 (n=16) at 4 h, and 0.83±0.03 (n=16), and 0.90±0.02 (n=16) at 8 h by dexamethasone or indomethacin alone, respectively (Figs 3,5) . Combined administration of dexamethasone and rofecoxib also caused severe ductal constriction, with a DA/PA ratio of 0.73±0.04 (n=16) at 2 h, 0.66±0.04 (n=16) at 4 h, and 0.64±0.07 (n=16) at 8 h, whereas the DA/PA ratio decreased only to 0.85±0.03 (n=24) and 0.85±0.03 (n=16) at 2 h, 0.76±0.03 (n=16) and 0.91±0.02 (n=14) at 4 h, and 0.83±0.03 (n=16) and 0.92±0.03 (n=16) at 8 h by dexamethasone or rofecoxib alone, respectively (Fig 4) .
Discussion
The first significant finding in this study is that a clinical dose of dexamethasone caused ductal constriction similar to indomethacin in preterm and near-term fetal rats. Although the mechanism of steroid hormones in constricting the DA is not completely clear, Clyman et al suggested that transplacental hydrocortisone decreased the sensitivity of the ductal muscle to the dilatory effects of prostaglandin E2 (PGE2) in fetal lambs, 12 and Flower et al 13 and Kuehl et al 14 reported that steroids might also have a direct effect on the PDA, leading to closure, through interference with PG synthesis.
The second finding is that rofecoxib caused ductal constriction similar to indomethacin in preterm fetal rats. COX exists in 2 isoforms: COX-1 and COX-2. 8 COX-1 is a constitutive form of the enzyme that is widely expressed in tissues throughout the body, including the gastrointestinal tract, kidneys, and platelets. COX-2, a cytokine-inducible form of the enzyme, is expressed prominently in inflamed tissue. 10 Selective inhibition of COX-2 dose not seem to be associated with adverse effects on the gastrointestinal tract or blood platelets. [15] [16] [17] Non-selective NSAIDs inhibit the activity of both COX-1 and COX-2, so indomethacin causes gastrointestinal, kidney, and platelet dysfunction because of COX-1 inhibition. 9, 10 These observations lead to the hypothesis that selective COX-2 inhibitors possess antiinflammatory properties without side-effects. Takahashi et al showed that COX-2 inhibition constricted the fetal lamb DA in vitro and vivo, 18 which concords with the results of the present study. Furthermore, Clyman et al have shown that both COX-1 and COX-2 are expressed by cells of the fetal lamb DA; in addition, both COX-1 and COX-2 contribute to the PG production by the DA in vitro. 19 The third and most important finding in this study is that the DA of near-term fetal rats was constricted more with the combined administration of dexamethasone and indomethacin or dexamethasone and rofecoxib than with dexamethasone, indomethacin, or rofecoxib alone. PGE2 is essential for physiologic patency and dilatation of the fetal DA. Indomethacin inhibits COX and decreases the endogenous concentrations of PGE2, resulting in fetal DA constriction. As in fetal lambs given hydrocortisone, dexamethasone is assumed to decrease DA sensitivity to PGE2 in fetal rats, 12 a change in sensitivity that acts to augment DA constriction because of a decrease in PGE2. Thus, the combined administration of dexamethasone and indomethacin or dexamethasone and rofecoxib has a synergistic effect on the fetal DA. A limitation of the present study was that the drugs were administered to the pregnant rat and fetal plasma concentrations of circulating PGs were not measured.
Combined administration caused greater ductal constriction in the near-term than in the preterm rats in the present study. Momma et al showed that PG has a major role and nitric oxide (NO) has a minor role in dilating the DA in the near-term fetal rat, whereas the reverse applies to the preterm fetal rats. 20 The shift from NO to PGs in mediation of dilation of the fetal DA may be a preparative process for postnatal closure. The mechanism for the switch is not clear, but Yallampalli et al reported on uterine NO production in rats, suggesting that progesterone increases NO formation during pregnancy and that a rise in estrogen at term inhibits NO to initiate labor. 21 In the present study, although the fetal DA was constricted more in near-term rats than in preterm rats, combined administration may be useful for the treatment of PDA in premature infants because combined administration of dexamethasone and rofecoxib caused severe ductal constriction at 2 h in preterm rats.
Clinically, we propose that combined therapy with dexamethasone and indomethacin may be useful in constricting the PDA in place of indomethacin alone, which sometimes fails to close the PDA. Furthermore, we also suggest that combined therapy with dexamethasone and rofecoxib may be useful in constricting the PDA when indomethacin alone is contraindicated because of sideeffects such as renal failure, active bleeding, and thrombocytopenia. Although animal studies cannot be applied directly to the clinical situation, combined therapy may be an option in the medical management of PDA in the acute phase before considering surgical treatment.
